IP Library › Granted Patent US 11,622,957
Granted Patent B2
US 11,622,957 · App. 17/468,023 · Granted Apr 11, 2023

Formulations for treating cluster symptoms associated with autism spectrum disorder

Inventors: Oludare Odumosu (Newtown Square, PA); Erica Daniels (Newtown Square, PA); Zachary Swope (Newtown Square, PA); Megan Watkins (Newtown Square, PA)
Assignee: Ilera Therapeutics LLC
A61K31/352A61K31/015A61K31/045A61K31/05A61P25/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,622,957
App. No.
17/468,023
Granted
Apr 11, 2023
Kind
B2
Abstract

The present disclosure provides for pharmaceutical compositions useful for treating autism spectrum disorder. The pharmaceutical compositions comprise particular THC:CBD ratios and terpene profiles, which have been demonstrated effective at treating cluster symptoms associated with autism spectrum disorder.

Claims (19)

1. A method of improving communication in patients with autism spectrum disorder (ASD), said method comprising the steps of administering a pharmaceutical composition comprising:

(a) a Cannabinoid Profile comprising Tetrahydrocannabinol (THC) and Cannabidiol (CBD) at a THC:CBD ratio of 5:1 by weight; and

(b) a Terpene Profile comprising β-Caryophyllene (BCP), Myrcene, and α-Bisabolol.

2. The method of claim 1 , wherein the Terpene Profile of the pharmaceutical composition comprises 20%-40% BCP, 20%-40% Myrcene, and 20%-40% α-Bisabolol, wherein the total of % BCP+% Myrcene+% α-Bisabolol=100%.

3. The method of claim 1 , wherein the Terpene Profile of the pharmaceutical composition comprises about 33% BCP by weight, about 34% Myrcene by weight, and about 33% α-Bisabolol by weight.

4. The method of claim 1 , wherein:

(a) the Cannabinoid Profile comprises about 8.33 mg/mL THC and about 1.67 mg/mL CBD.

5. The method of claim 1 , wherein:

(b) the Terpene Profile comprises about 1.8 mg/mL BCP, about 1.8 mg/mL Myrcene, and about 1.8 mg/mL α-Bisabolol.

6. The method of claim 1 , wherein:

(a) the Cannabinoid Profile comprises about 8.33 mg/mL THC and about 1.67 mg/mL CBD, and

(b) the Terpene Profile comprises about 1.8 mg/mL BCP, about 1.8 mg/mL Myrcene, and about 1.8 mg/mL α-Bisabolol.

7. The method of claim 1 , wherein the pharmaceutical composition comprises olive oil.

8. The method of claim 1 , wherein the pharmaceutical composition is grapefruit flavored.

9. The method of claim 1 , wherein the pharmaceutical composition is peppermint flavored.

10. The method of claim 1 , wherein the pharmaceutical composition is vanilla flavored.

11. The method of claim 1 , wherein the pharmaceutical composition is lemon flavored.

12. The method of claim 1 , wherein the pharmaceutical composition is orange flavored.

13. The method of claim 1 , wherein the pharmaceutical composition is ginger flavored.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2022
From: ODUMOSU, OLUDARE; SWOPE, ZACHARY; DANIELS, ERICA; WATKINS, MEGAN
To: ILERA THERAPEUTICS LLC
Reel/Frame 059698/0883 →
Continuity (4)
Continuation PCTUS2020021767 · Mar 9, 2020
Provisional Application 62852513 · May 24, 2019
Provisional Application 62815236 · Mar 7, 2019
Related Publication 20210401796A1 · Dec 30, 2021
Cited By (2)
US 12,213,985 US 12,569,505